Widespread anti-AAV antibodies (Abs) in humans pose a critical challenge for the translation of AAV gene therapies, limiting patient eligibility. In this study, non-human primates (NHPs) with pre-existing aAAV Abs were used to investigate the impact of aAAV9 Ab levels on the transduction efficiency of rAAV9 via systemic delivery. No significant differences were observed in vector genome (vg) biodistribution in animals with %1:400 total serum aAAV9-IgG compared to aAAV9-Ab-negative animals, following an intravenous (i.v.) rAAV9-hNAGLU op (codon-optimized human a-N-acetylglucosaminidase coding sequence cDNA) injection. Serum aAAV9-IgG at >1:400 resulted in a >200-fold decrease in vg in the liver, but had no significant effect on vg levels in brain and most of the peripheral tissues. Although tissue NAGLU activities declined significantly, they remained above endogenous levels. Notably, there were higher vg copies but lower NAGLU activity in the spleen in NHPs with >1:400 aAAV9 Abs than in those with %1:400 Abs. We demonstrate here the presence of a threshold of pre-existing aAAV9 Abs for diminishing the transduction of i.v.-delivered AAV vectors, supporting the expansion of patient eligibility for systemic rAAV treatments. Our data also indicate that high pre-existing aAAV9 Abs may promote phagocytosis and that phagocytized vectors are not processed for transgene expression, suggesting that effectively suppressing innate immunity may have positive impacts on transduction efficiency in individuals with high Ab titers.
INTRODUCTION
Adeno-associated virus (AAV) vectors are promising as effective gene-delivery tools for long-term transduction in a broad range of tissues. They have displayed efficacy and safety after systemic delivery in numerous pre-clinical disease models and in clinical trials, particularly for monogenic diseases. [1] [2] [3] [4] [5] [6] Recognition of the transblood-brain barrier neurotropic properties of the AAV9 vector 7, 8 has led to significant advancements in AAV gene delivery for diseases with global or broad neuropathy in the CNS, demonstrating promising clinical potential. [4] [5] [6] These studies have led to the translation of systemic AAV9 gene delivery to a phase I clinical trial in patients with type 1 spinal muscular atrophy (SMA1; ClinicalTrials.gov: NCT02122952); 9 phase 1/2 trials in patients with MPS IIIA (ClinicalTrials.gov: NCT02716246), 10 MPS IIIB (ClinicalTrials.gov: NCT03315182), 5, 11, 12 and MPS II (IND17838); 13 and intrathecal gene-delivery clinical trials in patients with giant axonal neuropathy (NCT02362438) 14 and Batten disease (CLN6; ClinicalTrials.gov: NCT02725580).
As effective AAV gene therapy approaches become available for clinical application, pre-existing host humoral immunity against AAV poses critical challenges. Although it has no known pathogenesis, AAV is widespread in humans, and more than 90% of the adult population is naturally infected, with a high prevalence of antibodies (Abs) to various AAV serotypes. 15, 16 Although AAV2 is the most prevalent serotype in humans, cross-reactivity among different serotypes [15] [16] [17] [18] reduces the potential utility of AAV vectors packaged in capsids of alternative serotypes. Anti-AAV Abs (aAAV Abs) also arise following recombinant AAV (rAAV) gene delivery, making re-administration unfeasible. Various clinically relevant models have been established to characterize anti-AAV humoral immunity and cross-reactivity. 17, [19] [20] [21] [22] [23] No effective approaches are currently available to overcome pre-existing aAAV Abs, which diminish the efficacy of systemically delivered rAAV vectors and broadly limit their application in terms of patient eligibility in clinical trials. The prevalence of pre-existing aAAV Abs is high in humans, but the serum levels vary greatly among individuals. 15, 16, 24 To date, in the majority of U.S. Food and Drug Administration (FDA)-approved systemic rAAV gene therapy clinical trials, the enrollment criteria have been set at either <1:10 aAAV neutralizing Ab (NAb) titer or <1:100 total aAAV-IgG titer, which would exclude a significant number of patients for the initial dosing and all individuals who need re-administration.
Our previous studies in non-human primates (NHPs) showed that low levels of pre-existing aAAV9-IgG (<1:50) had no detectable impact on tissue transgene expression following systemic rAAV9 vector delivery. 12 Notably, a higher level of pre-existing aAAV9 Abs blocked transduction in the liver, but had very limited impact on transduction in the CNS and most of the tested different tissues in NHPs after injection of an intravenous (i.v.) vector. 12 Given the relatively broad, but not necessarily reciprocal, cross-reactivity among AAV serotypes, some pre-existing aAAV9 Abs may be attributable to infections with other AAV serotypes. 15, 25 It is unclear regarding the lowest levels of pre-existing Abs that have a significant impact on rAAV after systemic delivery, particularly in the context of Abs arising from natural AAV infection.
For clinical relevance in this study, we used NHPs that have naturally occurring pre-existing aAAV Abs similar to humans to investigate the impact of aAAV9 Ab levels on the transduction efficiency of systemically delivered rAAV9 vector. Our data demonstrate that total aAAV9-IgG at %1:400 had no detectable impact on tissue transduction efficiency following an i.v. rAAV9 vector delivery.
RESULTS
To determine the impact of pre-existing aAAV Abs on systemic rAAV gene delivery, we performed i.v. injection of rAAV9 vector in 2-to 2.6-year-old Macaca cynomolgus monkeys that presented various levels of pre-existing aAAV9 Abs in serum screening by ELISA for total Ig against AAV9. In general, an aAAV Ab titer <1:50 was considered negative. Seven animals with 1:100-1:6,400 titers of aAAV9-IgG were selected and used in this study. All seven animals were treated with an i.v. injection of 1 Â 10 13 vg (vector genomes)/kg rAAV9/chicken b-actin/codon-optimized human a-N-acetylglucosaminidase coding sequence cDNA (rAAV9-CBAhNAGLU op ) vector. The animals were observed daily for well-being and behavior after the vector treatment. Necropsy was performed at 5 weeks after injection (p.i.) for tissue analyses of transgene expression, vector biodistribution, and histopathology. Tissues from four NHPs from a previous study were used as controls, including two non-treated animals and two animals that had been aAAV9 Ab negative at the time that they received an i.v. injection of a similar rAAV9 vector, rAAV9-cytomegalovirus (CMV)-hNAGLU (produced by SAB Tech, Philadelphia, PA), at 1 Â 10 13 vg/kg and had been terminated at 6 weeks or 3 months p.i.
12 Table 1 summarizes the study design.
Differential Impacts of Pre-existing aAAV9 Abs on the Transduction Efficiency of a Systemically Delivered rAAV9 Vector Real-time qPCR was performed to determine the amount of rAAV9-CBA-hNAGLU op vector entering the CNS versus the somatic tissues. Figure 1 shows the differential biodistribution of vgs in different tissues following an i.v. vector injection in NHP subjects, with or without pre-existing aAAV9 Abs. Notably, no detectable differences were observed in vg levels in the brain or any tested peripheral tissues in animals with %1:400 titers of pre-existing aAAV9-IgG (Figure 1 ). In general, in these animals, the highest vector concentration was detected in the liver, followed by the spleen, heart, brain, and other tissues ( Figure 1 ).
In three NHPs that had relatively higher serum aAAV9-IgG titers (1:800-1:6,400), transduction in the liver, as measured by vg copy numbers, was essentially ablated. (Figure 1 ). However, no significant differences were detected in most of the tested somatic tissues, including brain, heart, lung, kidney, intestine, muscle, and pancreas, among all seven NHP subjects with different titers of pre-existing aAAV9-IgG (Figure 1 ). These data suggest that the high pre-existing aAAV9 Abs have less impact on AAV9 transduction in the CNS and most of the somatic tissue than in the liver.
Notably, unlike other tissues, the vg levels in the spleen in the three animals with 1:800-1:6,400 pre-existing aAAV9-IgG trended higher (p = 0.062) than in the animals with 1:400 or lower titers (Figure 1 ), similar to our previously published data. 12 Using the NAGLU enzyme activity assay, we observed significantly lower NAGLU activity levels in all tested tissues in the three NHPs with 1:800-1:6,400 pre-existing aAAV9-IgG, in comparison to those in animals with 1:400 or lower (Figure 2 ), although the tissue NAGLU activity levels in animals with 1:800-1:6,400 aAAV9-IgG remained above normal wild-type (WT) levels ( Figure 2 ). In general, the tissue NAGLU activity levels correlated with the vector biodistribution data, with the exception of the spleen (Figures 1  and 2 ), though the differences in tissue vg levels were not significant in the majority of the tested tissues ( Figure 1 ). Although tissue vg copy number and NAGLU activity level appeared to correlate in most of the tissues, further correlation analysis did not reach statistical significance, though the negative correlation in the spleen NHPs with low levels of pre-existing aAAV9-IgG (1:100-1:400); VC1 and -2: control tissues from two NHPs treated with a similar rAAV9-CMV-hNAGLU vector in a previous study; NT1 and -2: control tissues from two non-treated NHPs used in a previous study.
approached significance. Similar to our previously published data, we saw higher vector copy numbers (p = 0.062; Figure 1 ), but lower NAGLU activity, in spleens from the animals with R1:800 aAAV9 Abs, compared with the animals with %1:400 aAAV9 Abs (p < 0.05; Figures 2 and 3 ). This suggests that pre-existing aAAV9 immunity may have driven higher levels of phagocytosis by splenocytes.
Further correlation analyses showed a trend toward negative correlation between serum pre-existing aAAV9 Abs and tissue AAV vg copy levels in the brain, liver, heart, kidney, and lung ( Figure 4 ), though it did not reach statistical significance (p > 0.05). These data further support a limited loss in transduction efficiency in most of these tissues in the presence of higher aAAV9 Abs ( Figure 1 ). The lack of statistical significance of the negative correlation between aAAV9 Ab titers and liver vg copy numbers appeared to be due to high individual variation in the low-aAAV9-Abs group animals ( Fig Furthermore, our data showed negative correlation of serum pre-existing aAAV9 Abs to tissue NAGLU activity in all tested tissues, though it did not reach statistical significance ( Figure 5 ). Notably, near-significant negative correlations were observed between serum aAAV9 Abs and NAGLU activity in the intestine (p = 0.062) and muscle (p = 0.079; Figure 5 ). from animals with 1:800-1:6,400 serum total aAAV9-IgG (n = 3); Ab-Low, tissues from animals with 1:100-1:400 serum total aAAV9-IgG (n = 4); Ab-Neg, tissues from aAAV9-IgG-negative NHPs from a previous study, treated with rAAV9-hNAGLU vector (n = 2).
No Detectable Systemic Toxicity in NHPs after an i. 
DISCUSSION
The most important outcome of this study is the demonstration of the threshold at which aAAV Abs significantly diminished the transduction efficiency of systemically delivered AAV vectors in NHPs. As effective AAV gene therapy products advance to clinical application, the high prevalence of pre-existing humoral immunity against AAV in humans impedes the translation of systemic AAV gene delivery for the treatment of human diseases. Although the serum pre-existing aAAV Ab titer varies greatly among individuals, 15, 16, 24 the enrollment criteria have been set at either <1:10, for the aAAV-NAb titer, or <1:100, for the total aAAV-IgG titer, in the majority of FDAapproved systemic AAV gene therapy clinical trials. These would exclude a significant number of patients for the initial dosing and all individuals who need re-administration. Using aAAV9-IgG as target, this study showed that low levels (%1:400) of pre-existing AAV9 Ab did not greatly affect tissue transduction in NHPs, suggesting that systemic rAAV9-hNAGLU op gene delivery may also be efficacious in treating patients with similarly low levels of pre-existing aAAV9 Abs. This is consistent with our previous observation in i.v. rAAV9-hNAGLU gene delivery in NHPs 12 and in a hemophilia gene therapy clinical trial in one patient who had low level (1:37) of Ab to the AAV8 vector. 1 These results support expansion of the enrollment criteria to %1:400 total aAAV-IgG titer for systemic rAAV gene-delivery clinical trials, to broaden patient eligibility for AAV gene therapy treatments, in this case, making more MPS IIIB patients eligible for systemic rAAV9-hNAGLU op gene delivery. Our recent studies showed that serum total aAAV9-IgG titers are % 1:400 in 74% of aAAV9 Abs-positive children, including MPS III patients and healthy children, 25 supporting the potential eligibility of the vast majority of the pediatric patient population for systemic rAAV9 gene-delivery treatments. Notably, this is a critical issue because no treatments are currently available for most neurogenetic diseases, were performed for tissue analyses at 1 month p.i. Tissues were assayed for NAGLU activity, expressed as U/mg protein: 1 U = 1 nmol 4MU released/h. H1-3, tissues from animals with 1:800-1:6,400 serum total aAAV9-IgG (n = 3); L1-4, tissues from animals with 1:100-1:400 serum total aAAV9-IgG (n = 4); NT, tissues from non-treated control animals from a previous study (n = 2).
including MPS III. Further, this could also benefit patients who may need re-administration down the road after the initial AAV vector treatment, when the rAAV gene-delivery-induced aAAV Abs titer declines to 1:400 or lower.
We also demonstrated that pre-existing aAAV9 Abs at a titer >1:400 (1:800-1:6,400) blocked transduction in the liver, but had relatively limited impact on transduction in the CNS and most of the tested peripheral tissues in NHPs after an i.v. rAAV9 vector injection. This is consistent with our previous observation in a single NHP. 12 Although the mechanisms are unclear regarding the disparity of aAAV9 Ab effects on transduction between the liver and other tissues, it may be related to the kinetics of rAAV9 CNS entry. It is possible that the initial vector-receptor binding is a rapid process in most tissues, allowing adsorption of vector before Ab-vector interaction. The liver has a double blood supply, with approximately 75% of total liver blood flow coming from the portal vein and the remainder coming from the hepatic artery. Therefore, in individuals with no or low levels of pre-existing aAAV Abs, AAV vectors enter the CNS and other peripheral organs exclusively via the arteries after an i.v. injection, whereas most of the AAV vector enters the liver through the portal vein. Because there is a natural delay in blood flow to the liver through the portal vein, compared with that from the hepatic artery, it is possible that Ab-vector binding occurs during this delay, in the presence of aAAV Abs at levels above the threshold (>1:400), leading to the clearance of the vectors in the blood flow before reaching the liver through the portal vein. Alternatively, the critical ligand for receptor binding in other tissues may be different from that for entry in the liver, such that it may be not be blocked efficiently by the Ab.
Whatever the mechanism, the possibility that the rAAV vector entering the CNS and other peripheral tissues is less susceptible to pre-existing aAAV Abs would potentially expand the patient population that could benefit from systemic AAV vector treatment in diseases where the liver is not the major target organ. This is also likely to offer significant benefit in the clinical setting, considering that almost half of the general human population is AAV9-Ab-positive at some level. Previous studies demonstrated broad Ab cross-reactivity across different AAV serotypes in humans. 15, 25 It is therefore possible that the low levels of pre-existing aAAV9 Abs detected in our NHP screen are largely attributable to cross-reacting Abs from infections with other AAV serotypes, with relatively lower affinity for AAV9 capsid. For patients with high levels of pre-existing aAAV9 Abs, immunomodulation regimens will be required prior to AAV vector administration, as shown in previous studies in animal models 18, 26, 27 and in patients with Pompe disease. 28, 29 Again, an exception observed in this study was that the NHPs with high pre-existing aAAV9-IgG (>1:400) had much higher vg copies (p = 0.062) but significantly lower NAGLU activity in the spleen, compared with animals with lower aAAV9 Abs (%1:400), indicating that the high vg in the spleen did not concordantly result in high levels were performed for tissue analyses at 1 month p.i. Data were analyzed for correlation between tissue vg (10 5 vg/mg gDNA) and serum levels of pre-existing aAAV9-Abs (ELISA titer). Solid circles, tissues from animals with 1:800-1:6,400 serum total aAAV9-IgG (n = 3); empty circles, tissues from animals with 1:100-1:400 serum total aAAV9-IgG (n = 4).
of rNAGLU expression. This is consistent with our previous observation, though with only 1 NHP available. 12 It is highly likely that most of the vector in the spleens of animals with high levels of Ab is a consequence of phagocytosis promoted by Ab binding to circulating vector as part of the initial innate immune response to vector delivery, whereas the phagocytized vectors in splenocytes were not further processed to achieve transgene expression. Therefore, immunomodulation targeting innate immunity before and after rAAV vector delivery may reduce the phagocytosis and increase the transduction efficiency of the treatment. Efforts are needed to develop a fine-tuned immune modulation regimen to eliminate the effects of phagocytosis and innate immune responses following the rAAV vector delivery.
In summary, this study demonstrated in NHPs the presence of a threshold of aAAV9 Abs for diminishing the transduction efficiency of systemically delivered AAV9 vectors, supporting the expansion of patient eligibility to include patients with %1:400 serum total aAAV9-IgG for AAV gene therapy treatment. We also demonstrated that aAAV9 Abs above the 1:400 threshold blocked transduction in the liver but had a more limited impact on the CNS and most of the tested peripheral tissues. This study also suggested that higher pre-existing aAAV9 Abs promotes phagocytosis by splenocytes and that phagocytized AAV vectors are not processed for transgene expression, supporting the possibility that suppressing innate immunity in individuals with high AAV Abs may have were performed for tissue analyses at 1 month p.i. Data were analyzed for correlation between tissue NAGLU activity (U/mg) and serum levels of pre-existing aAAV9 Abs (ELISA titer). Solid circles, tissues from animals with 1:800-1:6,400 serum total aAAV9-IgG (n = 3); empty circles, tissues from animals with 1:100-1:400 serum total aAAV9-IgG (n = 4).
www.moleculartherapy.org positive impacts on the transduction efficiency of systemic AAV gene delivery.
MATERIALS AND METHODS

Recombinant AAV Viral Vectors
An rAAV vector plasmid was constructed and used to produce a conventional single-strand rAAV9-CBA Table 1) . Prior to the experiments, the animals' sera were screened with an ELISA for pre-existing antibodies to the AAV9 capsid.
For vector delivery, veterinary staff anesthetized the subjects with an intramuscular (i.m.) (6 mg/kg). The subjects were then treated by i.v. injection of 1 Â 10 13 vg/kg rAAV9-CBA-hNAGLU op vector (in 5 mL saline) via the cephalic vein. Upon recovery, the subjects were returned to their housing and observed daily for well-being and behavior throughout the experiments.
Blood and Tissue Analyses
Blood draws were performed prior to vector injection and before necropsy at 5 weeks p.i. The subjects were euthanized by veterinary staff at 5 weeks p.i. for tissue analyses by i.v. injection of Euthasol (1 mL/10 lb). Brain, spinal cord, and multiple somatic tissues (liver, kidney, spleen, heart, lung, intestine, stomach, pancreas, and skeletal muscle) were harvested, either on dry ice and stored at À80 C, or in 4% paraformaldehyde at 4 C. As previously described, 12 each brain was divided into two hemispheres along the midline and then into multiple coronal slabs. Each slab from one sphere was further divided into matrices with 12-14 sections, and each section was harvested on dry ice and stored at À80 C. Brain slabs from the other sphere were fixed and stored in 4% paraformaldehyde.
NAGLU Activity Assay
Tissue samples were assayed for NAGLU enzyme activity according to a published procedure, with minor modifications. 30, 31 The assay measures 4-methylumbelliferone (4MU), a fluorescent product formed by hydrolysis of the substrate 4-methylumbellireyl-Nacetyl-a-D-glucosaminide. Tissue NAGLU activity is expressed as U/mg protein. Serum or CSF NAGLU activity is expressed as U/mL: 1 U = 1 nmol 4MU released per hour at 37 C.
Binding ELISA Serum samples were assayed by a binding ELISA to determine the levels of total IgG against AAV9, according to previously published procedures. 12 Empty capsid particles of AAV9 were obtained from SAB Tech and used as an antigen for the assay. Following incubation overnight at 4 C, the plates were washed with PBS containing 0.1% Tween-20 (pH 7.4; PBS-T) and blocked for 1 h with blocking buffer, PBS-T, and 5% dry milk. Two-fold serial dilutions (beginning at 1:50) of serum samples in blocking buffer were added to the plates and incubated at room temperature for 1 h. The plates were washed with PBS-T and then incubated with horseradish-peroxidase-conjugated anti-human IgG (Sigma-Aldrich, St Louis, MO) for 1 h at room temperature. After being washed with PBS-T, the plates were developed with 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB; Sigma-Aldrich, St Louis, MO) at room temperature for 5 min. The reaction was stopped by adding 1 M sulfuric acid. The absorbance was read at 450 nm on a plate reader. Serum total aAAV-IgG levels were expressed as an ELISA titer, based on the following calculation: (OD450-ag + À OD450-ag 
Real-Time qPCR
Total DNA was isolated from tissue samples of treated and nontreated NHP subjects using QIAGEN DNeasy columns. Brain DNA was isolated from cerebral cortex, hippocampus, and hypothalamus. The DNA samples were analyzed by qPCR, using Absolute Blue QPCR Mix (Thermo Scientific) and Applied Biosystems 7000 RealTime PCR System, following the procedures recommended by the manufacturer. Taqman primers specific for the CMV/CBA promoter were used to detect rAAV vgs: forward: . Genomic DNA from non-treated NHP tissues was used as controls for background levels and absence of contamination.
Histopathology
All collected tissues were processed to produce paraffin-embedded sections (4 mm) and then stained with H&E by the Morphology Core at NCH-RI. The sections were examined for histopathology under a microscope.
Statistical Analyses
Means, SD, and unpaired Student's t test were used to analyze serum Ab levels, tissue NAGLU activity, and vg bio-distribution data.
